Oblenio Bio
Oblenio Bio is a clinical-stage biotechnology company developing tri-specific antibody immunotherapies for refractory autoimmune diseases. Its lead candidate, LBL-051, is a tri-specific T-cell engager targeting BCMA, CD19, and CD3 to deplete B-cells and pursue long-term, drug-free remission and immune reset for patients. Founded with support from Aditum Bio and surfaced through the GV portfolio, Oblenio Bio operates in the life-sciences sector and does not currently publish a public developer or API program.
Oblenio Bio is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Immunotherapy, and Autoimmune.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API